Stem cell characteristics of dormant cells and cisplatin-induced effects on the stemness of epithelial ovarian cancer cells

Molecular Medicine Reports

Volumn 10, Issue 5, 2014, Pages 2495-2504

  Zhou, Nan ^a   Wu, Xiaohua ^a,b   Yang, Bo ^b   Yang, Xu ^b   Zhang, Dingding ^b   Qing, Guo ^c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

^c FIRST HOSPITAL OF SHIJIAZHUANG   (China)

Author keywords

Cancer stem cell; Chemotherapy; Epithelial ovarian cancer; PKH26; Tumor dormancy

Indexed keywords

CISPLATIN; FLUOROCHROME; HERMES ANTIGEN; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CELL CLONE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DENSITY; CERVICAL SPINE DISLOCATION; COLONY FORMATION; CONTROLLED STUDY; DROWSINESS; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; MOUSE; NONHUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; SKIN DISCOLORATION; STEM CELL; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANIMAL; CANCER STEM CELL; CELL CYCLE; DRUG EFFECTS; DRUG SCREENING; HUMAN; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; FEMALE; HUMANS; MICE, NUDE; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907188826     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2483     Document Type: Article

References (41)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
2. Levanon K, Crum C and Drapkin R: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26: 5284-5293, 2008.
3. Thigpen JT, Aghajanian CA, Alberts DS, et al: Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 96: 10-18, 2005.
4. Aguirre Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846, 2007.
5. Bhattacharyya S and Khanduja KL: New hope in the horizon: cancer stems cells. Acta Biochim Biophys Sin (Shanghai) 42: 237-242, 2010.
6. Pelayo R, Miyazaki K, Huang J, et al: Cell cycle quiescence of early lymphoid progenitors in adult bone marrow. Stem Cells 24: 2703-2713, 2006.
7. Yahata T, Muguruma Y, Yumino S, et al: Quiescent human hematopoietic stem cells in the bone marrow niches organize the hierarchical structure of hematopoiesis. Stem Cells 26: 3228-3236, 2008.
8. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008.
9. Morel AP, Lièvre M, Thomas C, et al: Generation of breast cancer stem cells through epithelial mesenchymal transition. PLoS One 3: e2888, 2008.
10. Hellsten R, Johansson M, Dahlman A, Sterner O and Bjartell A: Galiellalactone inhibits stem cell like ALDH positive prostate cancer cells. PLoS One 6: e22118, 2011.
11. Belton A, Gabrovsky A, Bae YK, et al: HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One 7: e30034, 2012.
12. Rosen JM and Jordan CT: The increasing complexity of the cancer stem cell paradigm. Science 324: 1670-1673, 2009.
13. Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol 9: 1191-1197, 2008.
14. Bapat SA: Human ovarian cancer stem cells. Reproduction 140: 33-41, 2010.
15. Lendahl U, Zimmerman LB and McKay RD: CNS stem cells express a new class of intermediate filament protein. Cell 60: 585-595, 1990.
16. Ishiwata T, Matsuda Y and Naito Z: Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J Gastroenterol 17: 409-418, 2011.
17. de Jong J and Looijenga LH: Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: history and future. Crit Rev Oncog 12: 171-203, 2006.
18. Hombach Klonisch S, Paranjothy T, Wiechec E, et al: Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch Immunol Ther Exp (Warsz) 56: 165-180, 2008.
19. Bapat SA, Mali AM, Koppikar CB and Kurrey NK: Stem and progenitor like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65: 3025-3029, 2005.
20. Sayed SI, Dwivedi RC, Katna R, et al: Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer. Oral Oncol 47: 237-243, 2011.
21. Yasui W, Sentani K, Sakamoto N, et al: Molecular pathology of gastric cancer: research and practice. Pathol Res Pract 207: 608-612, 2011.
22. Matsuda Y, Kure S and Ishiwata T: Nestin and other putative cancer stem cell markers in pancreatic cancer. Med Mol Morphol 45: 59-65, 2012.
23. Ma L, Lai D, Liu T, et al: Cancer stem like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin (Shanghai) 42: 593-602, 2010.
24. Reber L, Da Silva CA and Frossard N: Stem cell factor and its receptor c Kit as targets for inflammatory diseases. Eur J Pharmacol 533: 327-340, 2006.
25. Yue Z, Jiang TX, Widelitz RB and Chuong CM: Mapping stem cell activities in the feather follicle. Nature 438: 1026-1029, 2005.
26. Martin Padura I, Marighetti P, Agliano A, et al: Residual dormant cancer stem cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest 92: 952-966, 2012.
27. Gao MQ, Choi YP, Kang S, Youn JH and Cho NH: CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29: 2672-2680, 2010.
28. Patel P and Chen EI: Cancer stem cells, tumor dormancy, and metastasis. Front Endocrinol (Lausanne) 3: 125, 2012.
29. Páez D, Labonte MJ, Bohanes P, et al: Cancer dormancy: A model of early dissemination and late cancer recurrence. Clin Cancer Res 18: 645-653, 2012.
30. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
31. Martin LP, Hamition TC and Schilder RJ: Platinum resistance: The role of DNA repair pathways. Clin Cancer Res 14: 1291-1295, 2008.
32. Kusumbe AP and Bapat SA: Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 69: 9245-9253, 2009.
33. Fleuren GJ, Gorter A, Kuppen PJ, Litvinov S and Warnaar SO: Tumor heterogeneity and immunotherapy of cancer. Immunol Rev 145: 91-122, 1995.
34. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
35. Yaqui Beltrán A, He B and Jablons DM: The role of cancer stem cells in neoplasia of the lung: past, present and future. Clin Transl Oncol 10: 719-725, 2008.
36. Shackleton M: Normal stem cells and cancer stem cells: similar and different. Semin Cancer Biol 20: 85-92, 2010.
37. Dalerba P, Cho RW and Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284, 2007.
38. Friel AM, Sergent PA, Patnaude C, et al: Functional analyses of the cancer stem cell like properties of human endometrial tumor initiating cells. Cell Cycle 7: 242-249, 2008.
39. Hermann PC, Huber SL, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323, 2007.
40. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.
41. Gilbertson RJ and Graham TA: Cancer: Resolving the stem cell debate. Nature 488: 462-463, 2012.